Iodohexestrols. II. Characterization of the Binding and Estrogenic Activity of Iodinated Hexestrol Derivatives, in Vitro and in Vivo
Overview
Affiliations
The affinity of ortho-iodinated hexestrols for the estrogen binding protein from rat uterus, determined by competitive binding assay, decreases with progressive iodine substitution; 3-iodohexestrol (I-Hex) has a binding affinity 42% that of estradiol. Analysis of [3-H]-I-Hex binding in rat uterine cytosol by sucrose density gradient centrifugation shows both an estrogen-specific binding component (8 S) and a more abundant component (4 S) that is not estrogen specific. Scatchard analysis indicates that this latter binding is of high affinity (Kd equals to 3.7-8.3 times 10- minus-9 M) but is not uterine specific. Polyacrylamide gel electrophoresis shows that most of the [3-H]-I-Hex binding activity in serum and uterine cytosol is distinct from and anodic to the principal protein component (albumin), and that is comigrates with [14-C]thyroxine binding activity. In in vitro incubation of rat uteri, I-Hex can block the specific uptake of [3-H]estradiol into the nuclear fraction; it itself causes a translocation of estrogen-specific binding capacity (as measured by exchange) from cytoplasm to nuclei, and can induce the synthesis of an estrogen-specific uterine protein, all under conditions where it is not metabolically deiodinated to hexestrol. The uterotrophic activities of the iodohexestrols are in most cases comparable to that expected on the basis of their competitive binding affinities. However, selective, estrogen-specific uptake of [3-H]-I-Hex into rat uterus, either in vitro or in vivo, cannot be demonstrated.
Katzenellenbogen J Cancers (Basel). 2020; 12(8).
PMID: 32718075 PMC: 7465097. DOI: 10.3390/cancers12082020.
Katzenellenbogen J Nucl Med Biol. 2020; 92:24-37.
PMID: 32229068 PMC: 7442693. DOI: 10.1016/j.nucmedbio.2020.02.007.
Targeted functional imaging in breast cancer.
Kumar R Eur J Nucl Med Mol Imaging. 2007; 34(3):346-53.
PMID: 17404770 DOI: 10.1007/s00259-006-0284-2.
Mankoff D, Dehdashti F, Shields A Neoplasia. 2000; 2(1-2):71-88.
PMID: 10933070 PMC: 1531868. DOI: 10.1038/sj.neo.7900075.
Tarle M, Padovan R, Spaventi S Eur J Nucl Med. 1981; 6(2):79-83.
PMID: 7202428 DOI: 10.1007/BF00253718.